GSK to pay $300M to license drug it sees as potential lupus treatment
BioPharma Drive: Drug Pricing
OCTOBER 29, 2024
The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.
Let's personalize your content